Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously.
Clinical Cancer Research.
Times cited: 589
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Times cited: 296
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 54
Accumulation of α- and β-globin messenger RNAs in mouse erythroleukemia cells.
Clinics in Geriatric Medicine.
Times cited: 50